Effect of Flow Rate on In Vitro Aerodynamic Performance of NEXThaler® in Comparison with Diskus® and Turbohaler® Dry Powder Inhalers
Open Access
- 1 April 2016
- journal article
- research article
- Published by Mary Ann Liebert Inc in Journal of Aerosol Medicine and Pulmonary Drug Delivery
- Vol. 29 (2), 167-178
- https://doi.org/10.1089/jamp.2015.1220
Abstract
Background: European and United States Pharmacopoeia compendial procedures for assessing the in vitro emitted dose and aerodynamic size distribution of a dry powder inhaler require that 4.0 L of air at a pressure drop of 4 kPa be drawn through the inhaler. However, the product performance should be investigated using conditions more representative of what is achievable by the patient population. This work compares the delivered dose and the drug deposition profile at different flow rates (30, 40, 60, and 90 L/min) of Foster NEXThaler® (beclomethasone dipropionate/formoterol fumarate), Seretide® Diskus® (fluticasone propionate/salmeterol xinafoate), and Symbicort® Turbohaler® (budesonide/formoterol fumarate). Methods: The delivered dose uniformity was tested using a dose unit sampling apparatus (DUSA) at inhalation volumes either 2.0 or 4.0 L and flow rates 30, 40, 60, or 90 L/min. The aerodynamic assessment was carried out using a Next Generation Impactor by discharging each inhaler at 30, 40, 60, or 90 L/min for a time sufficient to obtain an air volume of 4 L. Results: Foster® NEXThaler® and Seretide® Diskus® showed a consistent dose delivery for both the drugs included in the formulation, independently of the applied flow rate. Contrary, Symbicort® Turbohaler® showed a high decrease of the emitted dose for both budesonide and formoterol fumarate when the device was operated at airflow rate lower that 60 L/min. The aerosolizing performance of NEXThaler® and Diskus® was unaffected by the flow rate applied. Turbohaler® proved to be the inhaler most sensitive to changes in flow rate in terms of fine particle fraction (FPF) for both components. Among the combinations tested, Foster NEXThaler® was the only one capable to deliver around 50% of extra-fine particles relative to delivered dose. Conclusions: NEXThaler® and Diskus® were substantially unaffected by flow rate through the inhaler in terms of both delivered dose and fine particle mass.Keywords
This publication has 36 references indexed in Scilit:
- Back to the Future: Inhaled Drug ProductsJournal of Pharmaceutical Sciences, 2013
- Lung penetration and patient adherence considerations in the management of asthma: role of extra fine formulationsJournal of Asthma and Allergy, 2013
- Effect of Device Design on the In Vitro Performance and Comparability for Capsule-Based Dry Powder InhalersThe AAPS Journal, 2012
- Effect of Sampling Volume on Dry Powder Inhaler (DPI)-Emitted Aerosol Aerodynamic Particle Size Distributions (APSDs) Measured by the Next-Generation Pharmaceutical Impactor (NGI) and the Andersen Eight-Stage Cascade Impactor (ACI)AAPS PharmSciTech, 2012
- Endothelial-monocyte activating polypeptide II disrupts alveolar epithelial type II to type I cell transdifferentiationRespiratory Research, 2012
- Step-down from high dose fixed combination therapy in asthma patients: a randomized controlled trialRespiratory Research, 2012
- Aerosol drug delivery: developments in device design and clinical useThe Lancet, 2010
- Lung Deposition of BDP/Formoterol HFA pMDI in Healthy Volunteers, Asthmatic, and COPD PatientsJournal of Aerosol Medicine and Pulmonary Drug Delivery, 2010
- The DiskusTM: a review of its position among dry powder inhaler devicesPublished by Hindawi Limited ,2007
- Validation of a reverse-phase high performance liquid chromatographic method for concurrent assay of a weak base (salmeterol xinafoate) and a pharmacologically active steroid (fluticasone propionate)Journal of Pharmaceutical and Biomedical Analysis, 2006